LAWRENCE, Mass., March 08, 2018 (GLOBE NEWSWIRE) — Boston Therapeutics, Inc announces their new participation in MassBIO, an unparalleled network of innovative companies and industry thought leaders dedicated to advancing cutting-edge research and development for patients’ lives improvements. Expanding operations in the US, the company is participating locally in MassBIO where the vibrant Massachusetts biotechnology industry can help build company value with networking and events, visibility, information resources and access to capital.
Through the recent acquisition of CureDM, the company also enjoys membership in New Mexico BIO. With BIO participation in two states, Boston Therapeutics will be able to identify and network with the best local partners in the strategic planning of the upcoming clinical trials for both BTI-320 and BTI-420 in 2018. CEO Carl Rausch explains, “Building operations in the US is part of our strategy to leverage our strong relationship with our partners throughout Asia, including China, and we believe MassBIO is a great place to start. As a small yet global presence, it is our intention to provide unique solutions to the worldwide epidemic of diabetes and its complications.”
The company intends to participate in upcoming BIO events and form new partnerships as they continue to develop treatments, technology and innovative approaches to diabetes and related pathologies.
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.